NCCN updates two oncology guidelines
-
Last Update: 2020-07-06
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
the National Comprehensive Cancer Network (NCCN) recently published important updates to its Guidelines for Myeloding Syndrome (2007) and the Hidden PrimaryCancerGuidelines (2007)The Guidelines for Bone Marrow Dying Syndrome (2007) add B-serocellular mycosin as the recommended treatment for patients with mild moderate bone marrow dysplasia syndrome anemiaSingle-dose azacitidine and decitabine are used as primary treatment drugs for patients with INT-2 risk (a cancer gene) and high-risk bone marrow dysplasia syndromeThe "Hidden PrimaryTumorGuide (2007)" adds two new tablets for the preliminary evaluation of "Chemical Markers of Unknown Primary Cancer Immunorostic Tissue" and a new "Chemotherapy Principles" column, which refers chemotherapy as a recommended treatment for patients with a behavioral status of 0 to 2 and asymptomatic malignanttumor(Liu Yu)
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
